Protocol Ledger

NCT05254743 · Phase III · RECRUITING

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Interventional Phase III clinical trial protocol NCT05254743 sponsored by Eli Lilly and Company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-22 Enrollment: 737 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05254743
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)737 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05254743
Protocol FieldVerified Registry Value
NCT IdentifierNCT05254743
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment737 participants (ESTIMATED)
Registered Start Date2022-07-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05254743
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
Florida Cancer Specialists (Fort Myers)Fort Myers, FLOpen Hospital Dossier ->
Florida Cancer Specialists (West Palm Beach)West Palm Beach, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI